Relay Therapeutics ( NASDAQ:RLAY ) First Quarter 2024 Results Key Financial Results Revenue: US$10.0m (up by US$9.78m...
Despite Net Loss, Relay Therapeutics Reports Significant Revenue Growth and Robust Pipeline Progress
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 11.43% and 2,905.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?